JP2020536507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536507A5 JP2020536507A5 JP2020515692A JP2020515692A JP2020536507A5 JP 2020536507 A5 JP2020536507 A5 JP 2020536507A5 JP 2020515692 A JP2020515692 A JP 2020515692A JP 2020515692 A JP2020515692 A JP 2020515692A JP 2020536507 A5 JP2020536507 A5 JP 2020536507A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 127
- 102000025171 antigen binding proteins Human genes 0.000 claims description 106
- 108091000831 antigen binding proteins Proteins 0.000 claims description 106
- 102000003859 Claudin-6 Human genes 0.000 claims description 65
- 108090000229 Claudin-6 Proteins 0.000 claims description 65
- 210000004027 cell Anatomy 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 24
- 108020001507 fusion proteins Proteins 0.000 claims description 21
- 102000037865 fusion proteins Human genes 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 17
- 102000004106 Claudin-3 Human genes 0.000 claims description 15
- 108090000599 Claudin-3 Proteins 0.000 claims description 15
- 108090000601 Claudin-4 Proteins 0.000 claims description 15
- 102000004161 Claudin-4 Human genes 0.000 claims description 15
- 108050007295 Claudin-9 Proteins 0.000 claims description 15
- 102000018157 Claudin-9 Human genes 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 10
- 230000004614 tumor growth Effects 0.000 claims description 9
- 241000699670 Mus sp. Species 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 239000006143 cell culture medium Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 description 11
- 230000002611 ovarian Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 6
- 238000012875 competitive assay Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000005265 lung cell Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000003443 bladder cell Anatomy 0.000 description 2
- 210000005168 endometrial cell Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102100032306 Aurora kinase B Human genes 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024099523A JP2024150445A (ja) | 2017-09-18 | 2024-06-20 | クローディン６抗体及びがんを治療するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560143P | 2017-09-18 | 2017-09-18 | |
| US62/560,143 | 2017-09-18 | ||
| PCT/US2018/051610 WO2019056023A2 (en) | 2017-09-18 | 2018-09-18 | ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024099523A Division JP2024150445A (ja) | 2017-09-18 | 2024-06-20 | クローディン６抗体及びがんを治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536507A JP2020536507A (ja) | 2020-12-17 |
| JP2020536507A5 true JP2020536507A5 (https=) | 2021-10-28 |
| JP7599332B2 JP7599332B2 (ja) | 2024-12-13 |
Family
ID=65723110
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515692A Active JP7599332B2 (ja) | 2017-09-18 | 2018-09-18 | クローディン６抗体及びがんを治療するための方法 |
| JP2024099523A Pending JP2024150445A (ja) | 2017-09-18 | 2024-06-20 | クローディン６抗体及びがんを治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024099523A Pending JP2024150445A (ja) | 2017-09-18 | 2024-06-20 | クローディン６抗体及びがんを治療するための方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20200291111A1 (https=) |
| EP (2) | EP4435009A3 (https=) |
| JP (2) | JP7599332B2 (https=) |
| KR (2) | KR20250050137A (https=) |
| CN (2) | CN118667021A (https=) |
| AU (2) | AU2018334434B2 (https=) |
| BR (1) | BR112020005196A2 (https=) |
| CA (1) | CA3076207A1 (https=) |
| CZ (1) | CZ2021138A3 (https=) |
| DK (1) | DK3826667T3 (https=) |
| ES (1) | ES2986343T3 (https=) |
| FI (1) | FI3826667T3 (https=) |
| GB (1) | GB202103867D0 (https=) |
| HU (1) | HUE067603T2 (https=) |
| IL (2) | IL273196B2 (https=) |
| MX (2) | MX2020002921A (https=) |
| NO (1) | NO20210351A1 (https=) |
| PL (1) | PL3826667T3 (https=) |
| PT (1) | PT3826667T (https=) |
| SG (1) | SG11202002114RA (https=) |
| SI (1) | SI3826667T1 (https=) |
| WO (1) | WO2019056023A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL273196B2 (en) * | 2017-09-18 | 2024-11-01 | Univ California | Claudin6 antibodies and methods of treating cancer |
| IL301637B2 (en) | 2017-09-29 | 2024-10-01 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| KR102063341B1 (ko) * | 2018-12-31 | 2020-01-07 | 다이노나(주) | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 |
| EP3924389A4 (en) | 2019-02-15 | 2023-06-14 | Integral Molecular, Inc. | CLAUDIN-6 ANTIBODIES AND THEIR USES |
| JP7682797B2 (ja) * | 2019-03-20 | 2025-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン６二重特異性抗体 |
| AU2020241896A1 (en) * | 2019-03-20 | 2021-09-23 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
| US11834512B2 (en) | 2020-05-04 | 2023-12-05 | The Regents Of The University Of California | Inhibiting anti-ENPP1 antibodies |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| WO2023091512A2 (en) * | 2021-11-16 | 2023-05-25 | Allakos, Inc. | Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9 |
| KR20240153421A (ko) * | 2022-02-09 | 2024-10-22 | 세라 프로그노스틱스 인코포레이티드 | Shbg 및 ibp4 항체 및 이를 사용하는 방법 |
| EP4626933A1 (en) | 2022-11-30 | 2025-10-08 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
| WO2025075127A1 (ja) * | 2023-10-04 | 2025-04-10 | 公立大学法人福島県立医科大学 | がんのバイオマーカー及び抗体治療 |
| TW202542202A (zh) * | 2024-01-04 | 2025-11-01 | 美商翰森生物有限責任公司 | 抗體、抗原結合片段及其醫療用途 |
| WO2025162270A1 (zh) * | 2024-02-01 | 2025-08-07 | 江苏恒瑞医药股份有限公司 | 抗cldn6抗体、其抗体-药物偶联物及其医药用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| ATE92499T1 (de) | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| EP1053752A1 (en) | 1998-02-10 | 2000-11-22 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| CA2346866A1 (en) | 1998-10-16 | 2000-04-27 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Combination therapy with vip antagonist |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| DE60331455D1 (de) | 2002-10-04 | 2010-04-08 | Microchips Inc | Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation |
| JP5632582B2 (ja) * | 2006-12-14 | 2014-11-26 | 中外製薬株式会社 | 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断 |
| NZ580700A (en) | 2007-04-19 | 2012-01-12 | Dong A Pharm Co Ltd | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
| CN101918450A (zh) * | 2008-01-11 | 2010-12-15 | 国立大学法人东京大学 | 抗cldn6抗体 |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| US9321842B2 (en) * | 2011-05-13 | 2016-04-26 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| PE20160870A1 (es) * | 2013-11-06 | 2016-09-09 | Abbvie Stemcentrx Llc | Anticuerpos anti-claudina novedosos y metodos de uso |
| SI3126381T2 (sl) * | 2014-04-01 | 2022-05-31 | Biontech Cell&Gene Therapies Gmbh | Claudin-6-specifični imunoreceptorji in t-celični epitopi |
| IL273196B2 (en) * | 2017-09-18 | 2024-11-01 | Univ California | Claudin6 antibodies and methods of treating cancer |
-
2018
- 2018-09-18 IL IL273196A patent/IL273196B2/en unknown
- 2018-09-18 CN CN202410853420.8A patent/CN118667021A/zh active Pending
- 2018-09-18 ES ES18857242T patent/ES2986343T3/es active Active
- 2018-09-18 FI FIEP18857242.4T patent/FI3826667T3/fi active
- 2018-09-18 HU HUE18857242A patent/HUE067603T2/hu unknown
- 2018-09-18 CN CN201880073220.3A patent/CN111565744B/zh active Active
- 2018-09-18 PT PT188572424T patent/PT3826667T/pt unknown
- 2018-09-18 MX MX2020002921A patent/MX2020002921A/es unknown
- 2018-09-18 JP JP2020515692A patent/JP7599332B2/ja active Active
- 2018-09-18 SG SG11202002114RA patent/SG11202002114RA/en unknown
- 2018-09-18 NO NO20210351A patent/NO20210351A1/en not_active Application Discontinuation
- 2018-09-18 EP EP24169481.9A patent/EP4435009A3/en active Pending
- 2018-09-18 KR KR1020257011014A patent/KR20250050137A/ko active Pending
- 2018-09-18 KR KR1020207009742A patent/KR102793719B1/ko active Active
- 2018-09-18 PL PL18857242.4T patent/PL3826667T3/pl unknown
- 2018-09-18 IL IL313238A patent/IL313238A/en unknown
- 2018-09-18 US US16/648,428 patent/US20200291111A1/en not_active Abandoned
- 2018-09-18 BR BR112020005196-9A patent/BR112020005196A2/pt active Search and Examination
- 2018-09-18 DK DK18857242.4T patent/DK3826667T3/da active
- 2018-09-18 EP EP18857242.4A patent/EP3826667B1/en active Active
- 2018-09-18 WO PCT/US2018/051610 patent/WO2019056023A2/en not_active Ceased
- 2018-09-18 SI SI201831128T patent/SI3826667T1/sl unknown
- 2018-09-18 CA CA3076207A patent/CA3076207A1/en active Pending
- 2018-09-18 AU AU2018334434A patent/AU2018334434B2/en active Active
- 2018-09-18 GB GBGB2103867.4A patent/GB202103867D0/en active Pending
-
2020
- 2020-03-17 MX MX2025012685A patent/MX2025012685A/es unknown
-
2021
- 2021-03-19 CZ CZ2021138A patent/CZ2021138A3/cs unknown
-
2022
- 2022-04-13 US US17/719,609 patent/US20220372134A1/en not_active Abandoned
-
2023
- 2023-12-19 US US18/545,890 patent/US20240400674A1/en not_active Abandoned
-
2024
- 2024-06-20 JP JP2024099523A patent/JP2024150445A/ja active Pending
-
2025
- 2025-01-23 AU AU2025200467A patent/AU2025200467A1/en active Pending
- 2025-06-27 US US19/252,512 patent/US20250333501A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536507A5 (https=) | ||
| CN112703013B (zh) | Cd3抗原结合片段及其应用 | |
| CN105820251B (zh) | 具有共同轻链的双特异性抗体或抗体混合物 | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| CN113330036B (zh) | 结合pd-l1和ox40的双特异性抗体 | |
| JP2022523543A (ja) | 二機能性融合タンパク質及びその医薬的使用 | |
| JP2020515251A (ja) | Ｂ７−ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用 | |
| EP4458854A1 (en) | Gprc5d antibody and application thereof | |
| TW201942130A (zh) | 結合至ssea4的單株抗體及其用途 | |
| CN108178799B (zh) | 一种抗ca125糖类抗原的纳米抗体及其应用 | |
| KR20140027051A (ko) | 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체 | |
| JP2014515600A5 (https=) | ||
| WO2014068300A1 (en) | Anti-s100a4 antibody molecules and their uses | |
| CN116848147A (zh) | Cd19人源化抗体及其应用 | |
| KR20240109605A (ko) | 항-인간 cd3 항체 및 이의 응용 | |
| JP2023518225A (ja) | ムチン１７に対する抗体及びその使用 | |
| WO2024017326A1 (zh) | 抗gprc5d纳米抗体及其应用 | |
| CN115957319B (zh) | 一种抗nkg2a单克隆抗体的注射制剂 | |
| US20250043016A1 (en) | Tnfr2 binding molecule and use thereof | |
| CN111018989A (zh) | 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用 | |
| TW202000699A (zh) | 將前胃泌激素作為生物標記用於免疫療法的技術 | |
| WO2023125349A1 (zh) | 抗gucy2c抗体及其应用 | |
| US20230159652A1 (en) | Transferrin receptor 1 targeting for carcinogenesis prevention | |
| CN118772279B (zh) | 抗FGFR2b抗体或其抗原结合片段及其用途 | |
| KR20170138465A (ko) | Igf-1r 항체 및 암의 진단을 위한 그의 용도 |